Table 1 Patient demographics
From: Telemedicine in allergy/immunology in the era of COVID-19: a Canadian perspective
All assessments | Virtual assessments | In-person assessments | |
|---|---|---|---|
Number of patients, n (%) | 3342 | 1543 (46.2%) | 1799 (53.8%) |
Sex, n (%) | |||
Female | 1872 (56%) | 890 (57.7%) | 982 (54.6%) |
Male | 653 (42.3%) | 817 (45.4%) | |
Age, n (%) | |||
<18 years | 458 (29.7%) | 722 (40.1%) | |
≥18 years | 1085 (70.3) | 1077 (59.9%) | |
Primary diagnosis, n (%) | |||
Rhinitis | 788 (23.6%) | 329 (21.3%) | 459 (25.5%) |
Anaphylaxis | 637 (19%) | 230 (14.9%) | 407 (22.6%) |
Hives | 531 (15.9%) | 329 (21.3%) | 202 (11.2%) |
Adverse effects of drugs | 471 (14.1%) | 211 (13.7%) | 260 (14.5%) |
Asthma | 464 (13.9%) | 213 (13.8%) | 251 (14%) |
Bites, venomous | 158 (4.7%) | 40 (2.6%) | 118 (6.6%) |
Respiratory system, other | 108 (3.2%) | 87 (5.6%) | 21 (1.2%) |
Atopic dermatitis | 54 (1.6%) | 30 (1.9%) | 24 (1.3%) |
Seborrheic dermatitis | 51 (1.5%) | 26 (1.9%) | 25 (1.4%) |
Immunity disorder | 51 (1.5%) | 31 (2%) | 20 (1.1%) |
Other | 29 (0.9%) | 17 (1.1%) | 12 (0.7%) |